>If you wanted to promote anticoagulation, you might think of partially inhibiting FVIII.<
This is exactly what BioInvent and ThromboGenics are trying to do with TB-402, but it’s a novel—and high-risk—approach. It’s tantamount to inducing a mild, artificial state of hemophilia-A while hoping to avert the major-bleeding events typical of more severe manifestations of the disorder.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.